NCT00718575

Brief Summary

Standard liver retrieval procedures for transplantation from a deceased donor inevitably result in a "reperfusion injury" to the liver tissue. The purpose of this research study is to find out whether treatment of the liver with a "preconditioning" protocol before its removal from the donor will help reduce any of this injury. The "preconditioning" treatment being tested has two components. Firstly, a solution of glucose+insulin is infused and secondly, blood flow to the liver is stopped briefly (10 minutes) and then resumed. Both strategies, individually, have been shown to reduce liver tissue injury in human studies. We hypothesize that combining both strategies will have a clinical benefit to patients and will improve liver function following transplant.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Aug 2008

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 18, 2008

Completed
14 days until next milestone

Study Start

First participant enrolled

August 1, 2008

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

July 25, 2014

Status Verified

June 1, 2012

Enrollment Period

1.8 years

First QC Date

July 16, 2008

Last Update Submit

July 24, 2014

Conditions

Keywords

Liver DiseaseTransplantation

Outcome Measures

Primary Outcomes (1)

  • Reperfusion injury determined by peak AST

    first 24 hours post-operative

Secondary Outcomes (3)

  • Biliary Complications, infection and rejection

    first month post-transplantation

  • graft and patient survival; length of hospital stay; length of ICU stay

    30 days and 90 days post-transplantation

  • Liver ATP and glycogen content; blood cytokine levels; liver gene expression of pro- and anti-apoptotic genes

    immediately pre-removal and post- transplantation

Study Arms (2)

1

EXPERIMENTAL

Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ

Procedure: Glucose/Ischemic Preconditioning Pre-treatment

2

NO INTERVENTION

Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.

Interventions

A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.

1

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Recipient 18 years of age or older
  • Recipient with chronic end-stage liver disease
  • Deceased donor liver transplant
  • Recipient capable of providing written informed consent
  • Whole organ graft from donors aged 60 years or older

You may not qualify if:

  • Fulminant liver failure
  • Objection by any other member of the retrieval team
  • Split-liver grafts
  • Donor that has received total parenteral nutrition within 24hr of organ retrieval Donors from whom the pancreas and/or small bowel are also being retrieved

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Health Network (Toronto General Hospital)

Toronto, Ontario, M5G 2N2, Canada

Location

MeSH Terms

Conditions

Liver Diseases

Interventions

Glucose

Condition Hierarchy (Ancestors)

Digestive System Diseases

Intervention Hierarchy (Ancestors)

HexosesMonosaccharidesSugarsCarbohydrates

Study Officials

  • Markus Selzner, M.D.

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2008

First Posted

July 18, 2008

Study Start

August 1, 2008

Primary Completion

June 1, 2010

Study Completion

March 1, 2012

Last Updated

July 25, 2014

Record last verified: 2012-06

Locations